abstract |
There is provided a compound selected from the compounds of formula (I) and pharmaceutically acceptable salts, solvates and hydrates thereof, wherein R 1 , R 2 , R 3 and R 4 are herein defined. As defined in. Such compounds are inhibitors of vesicular monoamine transporter 2 (VMAT2) and have utility for treating, for example, neurological and psychological diseases and disorders. Also disclosed are compositions that include such compounds in combination with a pharmaceutically acceptable carrier, as well as methods for their use in a subject in need thereof. |